Atopic Dermatitis Market

Atopic Dermatitis Market Size (2023 to 2028)

As per our report, the global atopic dermatitis market size was valued at USD 13.47 billion in 2023. It is expected to grow at a CAGR of 14.5% and be worth USD 26.52 billion by 2028. Therefore, the market is expected to progress steadily through the forecast period.

Atopic Dermatitis is an inflammatory skin disease, and its severity varies from patient to patient. It usually begins in childhood and is mainly confined to the flexural surfaces of the body. It is highly prevalent and is more commonly known as eczema. Itching, redness of the skin, cracking, weeping, etc., are symptoms, and it is a long-term disease. Low humidity, cold weather, and seasonal allergies are the common causes of it, and the pattern of the disease and its severity determine the kind of treatment it ought to receive. The global Atopic Dermatitis industry encompasses all aspects of the research, development, manufacturing, and commercialization of products and therapies to treat this condition.

Atopic Dermatitis Market Share Insights:

• Based on the treatment type, the drug treatment segment dominated the market in 2022 with the largest market share of 76.86%.
• Based on the route of administration, the Topical segment had a significant market share of 68.88% in 2022.
• Based on the distribution channel, the Retail Pharmacies segment had a significant market share of 55.33% in 2022.
• The North American region led the market, accounting for the highest share of the global market in 2022. 

MARKET DRIVERS:

Increasing awareness of atopic dermatitis drives the market growth forward.

Increasing awareness of AD people using herbal medicine, natural ointment, and ultraviolet therapy boosts the market. Furthermore, medical institutions provide education about AD and its primary treatment at home. In addition, much research will find fast relief for the disease. All these factors drive the market forward. Instance, to bring awareness European people about AD, World Atopic Eczema Day was initiated in 2018 to increase awareness of the condition internationally and around Europe through an initiative organized by the European Federation of Allergy and Airways Diseases Patient Associations (EFA) and the International Coalition of Dermatology Patient Organizations (Global Skin).

The launch of biologics & small molecules, premium-priced drugs substituting generic first-line and second-line therapeutics, and improved diagnostics are propelling the growth of the global atopic dermatitis market. Growing skin allergies and chronic disorders are expected to accelerate the market’s growth rate. Atopic dermatitis disease severity ranges from patient to patient, and the treatment procedures involve the severity degree. Escalating expenditure on healthcare and the growing popularity of these treatment procedures through digital advertisements accelerate the global atopic dermatitis market growth.

In addition, the growing number of initiatives from various governments are expected to expand the growth scope of the global atopic dermatitis market. Furthermore, an increasing number of patients suffering from various skin disorders, changes in climatic conditions, and the rise in disposable income in both developed and developing countries are further expected to accelerate the market's growth rate. Besides, the emergence of the latest technologies in the medical sector and the introduction of innovative procedures magnify this market's growth. In addition, the growing incidence of atopic dermatitis in children is expected to boost the market.

MARKET RESTRAINTS:

Lack of skilled healthcare professionals

Skilled healthcare personnel is in short supply in under-developing regions. A sufficient number of training programs is one of the primary reasons for this shortage. Hence, healthcare facilities often need more skilled doctors to meet the standards of care. The government could provide numerous workforce enticements to improve performance in public-sector hospitals and health centers. Various developed nations address a similar issue by basing reimbursement on capitation and a pay-for-performance model to balance the necessity of expanding service against budget restrictions.

Rising complications and side effects after the treatment procedure in some people hinder the demand of the global atopic dermatitis market. In addition, oral medicine can have severe side effects when taken for a more extended period. Furthermore, the need for more skilled people in hospitals and clinics and fluctuations in economic strategies negatively impact the growth rate of the atopic dermatitis market. In addition, less availability of necessary equipment in rural areas remains challenging for the market players. Also, the high cost of the treatment procedures due to advanced features is declining the growth rate of this market.

MARKET OPPORTUNITIES:

Increasing government initiatives

Atopic dermatitis (AD), the leading cause of skin-related disease burdens worldwide, is rising in developing countries in Asia, Africa, Latin America, and the Middle East. Therefore, the governments of respected countries worldwide are taking initiatives to develop and bring awareness among the people about atopic dermatitis. For Instance, The Ministry of Health and Prevention, MoHAP, has recently signed a Memorandum of Understanding with the Sanofi Aventis Community and Axios Health Education Programs in which MoHAP will launch a new program named "Ea'nah" (Support) for patients with relapsed multiple sclerosis (RMS) and relapsed-remitting MS (RRMS), patients with mild to extreme eczema (atopic dermatitis) and patients with relapsed multiple sclerosis (RMS).

Impact of COVID-19 on the atopic dermatitis market:

The COVID-19 pandemic has impacted the global atopic dermatitis market unfavorably. Atopic dermatitis is a skin condition, and a considerable population worldwide is suffering from this disease. COVID-19 resulted negatively in the growth of the atopic dermatitis market. Primarily, the ecosystem of the supply chain has been poorly hampered by the COVID-19 pandemic, which resulted in a shortage of atopic dermatitis drugs and treatment procedures. In addition, the governments of several countries have made it mandatory for the public to maintain social distancing. Due to this, people suffering from atopic dermatitis have temporarily stopped visiting hospitals for disease monitoring and started looking for alternative ways to treat atopic dermatitis, negatively affecting the market growth. In addition, the COVID-19 pandemic delayed clinical trials to bring new drugs and treatment methods to the atopic dermatitis market. Likewise, the atopic dermatitis market has experienced a significant negative impact from the COVID-19 pandemic. However, considering the reduced impact of the COVID-19 pandemic, the atopic dermatitis market is expected to register a healthy CAGR during the forecast period.

REPORT COVERAGE:

This market research report on the global atopic dermatitis market has been segmented and sub-segmented into the following categories.

Atopic Dermatitis Market - By Treatment Type:

• Drug Treatment
• Radiation Treatment

Based on treatment type, the drug treatment segment held the largest market share in 2022, and the segment’s domination of the segment is likely to continue during the forecast period. The growing preference from people and healthcare providers to treat atopic dermatitis with drugs instead of radiation treatment and the rising prevalence of early-diagnosis diseases are majorly propelling segmental growth. In addition, increasing investments by key market participants and R&D institutes to develop new and effective drugs for atopic dermatitis contribute to the segment's growth rate. Drugs are believed to be more effective in treating symptoms of atopic dermatitis, such as itching, redness, and inflammation. Due to this, the adoption of drug treatment is higher than that of radiation treatment. The wider availability and accessibility of drugs for atopic dermatitis for patients is another major attribute promoting segmental growth.

The radiation treatment segment is expected to grow at a rate of 14.6% during the forecast period owing to the growing adoption of radiation treatment procedures for patients with severe or widespread disease. In addition, the growing awareness regarding the benefits of radiation treatment among the healthcare providers, such as being effective in reducing inflammation and itching and promoting the healing of the skin, are driving the adoption of radiation treatment.

Atopic Dermatitis Market - By Route of Administration:

• Topical
• Oral

Based on the administration route, the topical segment is anticipated to hold a major market share of the global atopic dermatitis market and is also expected to grow at a high CAGR of 14.7% during the forecast period. Topic treatments are available in creams, ointments, lotions, and gels and are believed to reduce inflammation, itching, and skin dryness effectively. The growing preference from healthcare providers to prescribe medication in topical options for atopic dermatitis patients is majorly driving segmental growth.

However, the oral segment is also predicted to showcase a steady CAGR during the forecast period, and the growth of the oral segment in the global atopic dermatitis market is expected to be seen in the coming years. If the skin disease is in an advanced stage, most healthcare provider gives oral pills to help control the symptoms. In addition, at-home therapies use this oral medication for moderate to severe atopic dermatitis.

Atopic Dermatitis Market - By Distribution Channel:

• Hospital pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on the distribution channel, the retail pharmacies segment captured a significant share of the worldwide market in 2022 and is expected to grow at a high CAGR of 14.7% during the forecast period. Retail pharmacies are popular among patients as they are convenient and easily accessible, one of the key factors propelling the segment's growth rate.

During the forecast period, the hospital pharmacies segment captured a significant share of the global atopic dermatitis market owing to the growing flow of patients to hospitals and increasing patient preference to obtain medications from hospital pharmacies. In addition, people believe hospital pharmacies are a trustworthy destination to purchase prescribed medications, driving segmental growth.

On the other hand, the online pharmacies segment is also expected to grow steadily during the forecast period owing to the growing awareness among people regarding online pharmacies and increasing willingness from people to use online channels to buy healthcare products.

Atopic Dermatitis Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

The North American atopic dermatitis market had a significant share of the global market in 2022 and is anticipated to register the lead during the forecast period. New product launches, early treatment adoption, and lifestyle changes are the reasons behind it. According to recent studies, forty percent of people in America are suffering from moderate to severe atopic dermatitis diseases and emotional burden in addition to pain, physical discomfort, and sleep disturbance for 16.8 million people in the US It is a skin disease that results in rashes and patches of itchy skin, mainly around the neck, face, and eyes. In addition, 18% of Canadians suffer from atopic dermatitis (AD). It is a visible skin disease that impacts the quality of life through depression, anxiety, and psychosocial issues. Health Canada has approved CIBINQO (abrocitinib) for treating atopic dermatitis patients aged 12 years and older. However, many Canadian AD patients want to connect with peers for further support and need mental health resources.

Globally, the European atopic dermatitis market is predicted to be the second-largest regional market during the forecast period. Heavy investment in R&D activities in this region is the cause of the observable trend mentioned above. As a result, European countries like Spain and the United Kingdom are expected to showcase promising growth from 2020 to 2025. Nearly 5 percent of German adults suffer from atopic dermatitis (AD). German people are using many treatments for these diseases. In addition to UV therapy and proactive topical therapy, the European guideline for treating AD include reactive topical therapy for mild AD or temporary eczema and proactive topical therapy for moderate AD. German people have so many guidelines for treatment. Systemic drugs and phototherapy are used for skin diseases. Unfortunately, German patients still suffer from a high burden of disease and a low quality of life, indicating insufficient medication. 

The Asia Pacific atopic dermatitis market is predicted to be the fastest-growing global atopic dermatitis treatment market at a CAGR of 15.7% in the abovementioned forecast. India is forecasted to register the highest CAGR during the same period. This region extension can be attributed to victims' significant unmet clinical needs, increasing spending on healthcare, and adequate treatment availability. Indian Dermatology Expert Board Members have provided several guidelines for atopic dermatitis. In India, advanced drugs and treatments are provided for PD diseases. Several hospitals are adopting treatment for this disease as more people suffer from AD. This mainly occurred due to climate changes in India. The incidence of AD in China has rapidly increased during the past ten years. Most people aged 10-30 years suffer from these diseases requiring treatment. Chinese Society of Dermatology Immunology Group developed guidelines for the Diagnosis and Treatment of Atopic Dermatitis in China. Rapid advances in diagnosing and treating AD in the past five years globally and in China will drive the market forward. AD is the second most skin disease in Japan. In Japan, most children suffer from this disease. In 2021, the Japanese Ministry of Health, Labour, and Welfare (MHLW) approved the CIBINQO drug, which is oral, for the treatment of moderate to severe atopic dermatitis (AD) in adults. Along with this, Moizerto® Ointment is also approved in Japan and is manufactured by Otsuka Pharmaceutical Co., Ltd. for people suffering from atopic dermatitis in 2021.

The Latin American atopic dermatitis market is expected to grow significantly in the next five years due to a rapidly growing population, changing lifestyles, and a paradigm shift towards western lifestyles; increasing R&D and a large target patient pool are attributable to the observable trend mentioned above. As per the reports, 8 percent of adults suffer from AD in Brazil. The causes of PD in Latin American countries are tropical, temperate, and cold temperatures, humidity, pollution, ultraviolet rays, average time spent indoors, and allergen exposure.

The MEA atopic dermatitis market is anticipated to grow sluggishly in the abovementioned forecast period.

KEY MARKET PARTICIPANTS AND COMPETITIVE LANDSCAPE:

The key players in the global atopic dermatitis market are working on new strategies such as acquisitions, mergers, business expansions, and others. In addition, many MNCs have looked at inorganic growth and acquired some excellent MNCs and local companies. The industry is characterized by evolving technology, and the companies exert their competitive advantage through their proprietary products.

In this report, some notable companies profiled in the global atopic dermatitis market are Novartis International AG, Sanofi, Pfizer, AbbVie Pharmaceuticals Pvt Ltd, Bausch Health Cos., Inc., Bristol-Myers Squibb Corporation, Regeneron pharma, Viatris Incorporation, LEO Pharma, and Dermavant Sciences.

Bausch Health Companies Inc. is one of the leading companies in the atopic dermatitis market and develops, produces, and sells pharmaceutical goods, including name-brand generic medications, primarily for skin conditions. Some of the company’s Atopic Dermatitis (Eczema) Treatment Products are Altreno Lotion, Elidel Cream, Onexton Gel, Xerese Cream, and others. Actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses are the disorders that the company's dermatology product line treats. The company’s focus is on spending a significant amount in research and development, helping them launch new products and treatments for atopic dermatitis.

RECENT MARKET DEVELOPMENTS:

• In February 2023, The FDA approved Pfizer Inc.'s supplemental New Drug Application (sNDA) for CIBINQO® (abrocitinib), increasing its indication to cover teenagers (12 to 18 years) with refractory, moderate-to-severe atopic dermatitis (AD)
• In February 2023, Dermavant Sciences announced the completion of patient recruitment in its ADORING 1 and 2 Phase 3 clinical studies of VTAMA (taping of) cream, 1% for the topical treatment of atopic dermatitis (AD) in children as young as two years old and adults.
• In January 2023, Sanofi announced that Dupixent® (dupilumab) was approved by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency and is now recommended for wider EU authorization to treat severe atopic dermatitis in children aged six months to 5 years who are candidates for systemic therapy.
• In January 2023, Sun Pharma, India's top drugmaker by market share in the domestic pharmaceutical (pharma) sector, stepped up its game in the US dermatology field with the $576 million acquisition of Concert Pharmaceuticals, Inc. (Concert).
• In June 2022, Regeneron Pharmaceuticals, Inc., and Sanofi announced that the US Food and Drug Administration (FDA) approved Dupixent for children aged six months to 5 years for people suffering from atopic dermatitis.
• In January 2022, Evelo Biosciences, Inc. developed SYNTAX medicines used as orally delivered treatments for inflammatory diseases such as moderate and severe atopic dermatitis.
• AbbVie Inc and Pfizer Inc (PFE.N) have manufactured drugs to treat atopic dermatitis, which the US Food and Drug Administration approved in 2022. This drug was treated for a patient not responding to previous treatments.
• Dupilumab is another drug approved to treat severe atopic dermatitis treatment.